{"id":"NCT04411641","sponsor":"Sanofi","briefTitle":"Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)","officialTitle":"A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-09-24","primaryCompletion":"2024-08-29","completion":"2024-08-29","firstPosted":"2020-06-02","resultsPosted":"2025-06-18","lastUpdate":"2025-07-02"},"enrollment":1131,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Non-relapsing Secondary Progressive Multiple Sclerosis"],"interventions":[{"type":"DRUG","name":"Tolebrutinib","otherNames":["SAR442168"]},{"type":"DRUG","name":"Placebo to match Tolebrutinib","otherNames":[]}],"arms":[{"label":"SAR442168","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Primary Objective:\n\nTo determine the efficacy of SAR442168 compared to placebo in delaying disability progression in NRSPMS\n\nSecondary Objective:\n\nTo evaluate efficacy of SAR442168 compared to placebo on clinical endpoints, magnetic resonance imaging (MRI) lesions, cognitive performance, physical function, and quality of life To evaluate safety and tolerability of SAR442168 To evaluate population pharmacokinetics (PK) of SAR442168 and relevant metabolites in NRSPMS and its relationship to efficacy and safety To evaluate pharmacodynamics (PD) of SAR442168","primaryOutcome":{"measure":"Time to Onset of 6-Month Confirmed Disability Progression (CDP) as Assessed by Expanded Disability Status Scale (EDSS)","timeFrame":"Baseline (Day 1) up to approximately 47 months","effectByArm":[{"arm":"DB: Placebo","deltaMin":11.97,"sd":null},{"arm":"DB: Tolebrutinib 60 mg","deltaMin":12.04,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0026"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":17},"locations":{"siteCount":306,"countries":["United States","Argentina","Australia","Austria","Belarus","Belgium","Bulgaria","Canada","China","Czechia","Denmark","Finland","France","Germany","Greece","Hungary","India","Israel","Italy","Japan","Lithuania","Netherlands","Norway","Poland","Portugal","Romania","Russia","Spain","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["40202696"],"seeAlso":["https://sanofi.trialsummaries.com/Study/StudyDetails?id=25250&tenant=MT_SNY_9011"]},"adverseEventsSummary":{"seriousAny":{"events":39,"n":375},"commonTop":["Covid-19","Urinary Tract Infection","Fall","Nasopharyngitis","Headache"]}}